The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.
Modern Grauer's gorillas have experienced a decline in genetic diversity, more so than mountain gorillas, even as both have experienced population decline.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
The court cited previous US Supreme Court rulings, including Mayo vs. Prometheus, in determining that certain claims of Illumina's patents were invalid.
The research highlighted particular challenges for gram-negative organisms among a population of higher-risk patients.
Foundation Medicine's assay detects genomic alterations in 324 cancer genes and serves as a companion diagnostic for patients with certain types of tumors.
A new analysis found kidney disease-related pathogenic or likely pathogenic variants in exomes for roughly 9 percent of individuals with chronic kidney disease.
Major EHR vendor Cerner would like to see the SMART on FHIR protocol take off as it seeks to make genomic data just another element of a patient's record.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Brad Wertz, chairman and founding investor of GenomOncology, will take over as CEO on Jan. 1, the Cleveland-based company announced. Manuel Glynias, GenomOncology's current CEO and founder, will remain president. Wertz has a history of scaling technology companies in various industries as they move from startup to growth phase, including bioinformatics software maker Acero.
The analysis found that charges for suspected genetic diseases account for between 11 percent and 46 percent of pediatric healthcare costs in the US.
Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.